Browse ACAD9

Summary
SymbolACAD9
Nameacyl-CoA dehydrogenase family, member 9
Aliases NPD002; MGC14452; acyl-Coenzyme A dehydrogenase family, member 9; very-long-chain acyl-CoA dehydrogenase VLC ......
Chromosomal Location3q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Mitochondrion
Domain PF00441 Acyl-CoA dehydrogenase
PF02770 Acyl-CoA dehydrogenase
PF02771 Acyl-CoA dehydrogenase
Function

Required for mitochondrial complex I assembly (PubMed:20816094, PubMed:24158852). Has a dehydrogenase activity on palmitoyl-CoA (C16:0) and stearoyl-CoA (C18:0). It is three times more active on palmitoyl-CoA than on stearoyl-CoA. However, it does not play a primary role in long-chain fatty acid oxidation in vivo (PubMed:20816094, PubMed:24158852). Has little activity on octanoyl-CoA (C8:0), butyryl-CoA (C4:0) or isovaleryl-CoA (5:0).

> Gene Ontology
 
Biological Process GO:0006631 fatty acid metabolic process
GO:0006635 fatty acid beta-oxidation
GO:0009062 fatty acid catabolic process
GO:0010257 NADH dehydrogenase complex assembly
GO:0016042 lipid catabolic process
GO:0016054 organic acid catabolic process
GO:0019395 fatty acid oxidation
GO:0030258 lipid modification
GO:0032981 mitochondrial respiratory chain complex I assembly
GO:0033108 mitochondrial respiratory chain complex assembly
GO:0033539 fatty acid beta-oxidation using acyl-CoA dehydrogenase
GO:0034440 lipid oxidation
GO:0044242 cellular lipid catabolic process
GO:0044282 small molecule catabolic process
GO:0046395 carboxylic acid catabolic process
GO:0055088 lipid homeostasis
GO:0072329 monocarboxylic acid catabolic process
GO:0097031 mitochondrial respiratory chain complex I biogenesis
Molecular Function GO:0000062 fatty-acyl-CoA binding
GO:0003995 acyl-CoA dehydrogenase activity
GO:0009055 electron carrier activity
GO:0016627 oxidoreductase activity, acting on the CH-CH group of donors
GO:0048037 cofactor binding
GO:0050660 flavin adenine dinucleotide binding
GO:0050662 coenzyme binding
GO:0052890 oxidoreductase activity, acting on the CH-CH group of donors, with a flavin as acceptor
GO:1901681 sulfur compound binding
Cellular Component GO:0005743 mitochondrial inner membrane
GO:0030425 dendrite
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-6799198: Complex I biogenesis
R-HSA-1430728: Metabolism
R-HSA-611105: Respiratory electron transport
R-HSA-163200: Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.
R-HSA-1428517: The citric acid (TCA) cycle and respiratory electron transport
Summary
SymbolACAD9
Nameacyl-CoA dehydrogenase family, member 9
Aliases NPD002; MGC14452; acyl-Coenzyme A dehydrogenase family, member 9; very-long-chain acyl-CoA dehydrogenase VLC ......
Chromosomal Location3q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ACAD9 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolACAD9
Nameacyl-CoA dehydrogenase family, member 9
Aliases NPD002; MGC14452; acyl-Coenzyme A dehydrogenase family, member 9; very-long-chain acyl-CoA dehydrogenase VLC ......
Chromosomal Location3q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ACAD9 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.62 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolACAD9
Nameacyl-CoA dehydrogenase family, member 9
Aliases NPD002; MGC14452; acyl-Coenzyme A dehydrogenase family, member 9; very-long-chain acyl-CoA dehydrogenase VLC ......
Chromosomal Location3q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ACAD9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2340.199
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3810.844
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1290.925
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.6840.117
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.5690.782
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.8380.766
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1060.747
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0650.963
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1670.916
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.3620.808
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0470.983
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.2190.00105
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ACAD9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.76.8-3.11
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.78.5-4.80.66
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.4015.40.482
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolACAD9
Nameacyl-CoA dehydrogenase family, member 9
Aliases NPD002; MGC14452; acyl-Coenzyme A dehydrogenase family, member 9; very-long-chain acyl-CoA dehydrogenase VLC ......
Chromosomal Location3q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ACAD9. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolACAD9
Nameacyl-CoA dehydrogenase family, member 9
Aliases NPD002; MGC14452; acyl-Coenzyme A dehydrogenase family, member 9; very-long-chain acyl-CoA dehydrogenase VLC ......
Chromosomal Location3q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ACAD9. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ACAD9.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolACAD9
Nameacyl-CoA dehydrogenase family, member 9
Aliases NPD002; MGC14452; acyl-Coenzyme A dehydrogenase family, member 9; very-long-chain acyl-CoA dehydrogenase VLC ......
Chromosomal Location3q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ACAD9. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolACAD9
Nameacyl-CoA dehydrogenase family, member 9
Aliases NPD002; MGC14452; acyl-Coenzyme A dehydrogenase family, member 9; very-long-chain acyl-CoA dehydrogenase VLC ......
Chromosomal Location3q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ACAD9 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolACAD9
Nameacyl-CoA dehydrogenase family, member 9
Aliases NPD002; MGC14452; acyl-Coenzyme A dehydrogenase family, member 9; very-long-chain acyl-CoA dehydrogenase VLC ......
Chromosomal Location3q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ACAD9 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolACAD9
Nameacyl-CoA dehydrogenase family, member 9
Aliases NPD002; MGC14452; acyl-Coenzyme A dehydrogenase family, member 9; very-long-chain acyl-CoA dehydrogenase VLC ......
Chromosomal Location3q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ACAD9 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.